Orthopaedics march on and cardiovascular keeps pace - Zimmer and Boston sales up a fifth after nine months
This article was originally published in Clinica
Executive Summary
UK discovery instrumentation and imaging agent group Amersham, which is to be acquired by General Electric, said its Amersham Health diagnostics division had sales of £235m ($398m) in the third quarter, up by 6% excluding currency fluctuation effects. Medical diagnostic products excluding Japan grew by 11% with patented products up by 19%. The group said its Visipaque non-ionic X-ray contrast media "continued excellent growth". CEO Sir William Castell said the company was on track to meet its full-year targets.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.